China 
Africa 
Explore chapters and articles related to this topic
Product: Alfa-Tox
Published in Charles R. Foden, Jack L. Weddell, First Responder’s Guide to Agricultural Chemical Accidents, 2018
Charles R. Foden, Jack L. Weddell
HEALTH HAZARD INFORMATION: Primary route of entry is dermal. World Health Organization recommends tlv: 0.2 mg/m3. Product is a cholinesterase inhibitor; may cause headache, constriction of pupils, salivation, muscular incoordination twitching, sweating, and vomiting.A physician should be contacted if any one develops any signs or symptoms and suspects that they are caused by exposure to this product.(ATROPINE SULFATE IS ANTIDOTE)
Characterization of the antioxidant activity, total phenolic content, enzyme inhibition, and anticancer properties of Achillea millefolium L. (yarrow)
Published in Instrumentation Science & Technology, 2022
Nagihan Karaaslan Ayhan, Merve Goksin Karaaslan Tunc, Samir Abbas Ali Noma, Ali Kurucay, Burhan Ates
Acetylcholinesterase (AChE, E.C.3.1.1.7) is a key cholinesterase that plays an important role in cholinergic transmission. Enzymes are expressed in all tissue cells but have less activity. Acetylcholinesterase enzyme is primarily in muscles, brain, and cholinergic neurons and is responsible for the rapid hydrolysis of acetylcholine (ACh) at synapses.[24] Indeed, in the late phase of Alzheimer’s disease (AD), AChE levels increase significantly. Cholinesterase inhibitors or anti-cholinesterase prevent the breakdown of the neurotransmitter butyrylcholine or acetylcholine. The cholinergic system, which plays a significant role in the regulation of cognition, learning, and memory processes, has been extensively studied for the design of Alzheimer’s disease drugs.[25]
Inhibition of enzymes important for Alzheimer’s disease by antioxidant extracts prepared from 15 New Zealand medicinal trees and bushes
Published in Journal of the Royal Society of New Zealand, 2020
Hafiz Majid, Filipa V. M. Silva
As of now, there are yet to develop therapeutic interventions to completely cure AD or to reverse the disease’s progression. Most existing treatments treat AD symptomatically and provide temporary relief for AD patients. Current therapies have been shown to increase the quality of life of AD patients, such as improving their mood, increasing their social interaction, and diminishing memory loss and confusion (Herrmann et al. 2011). According to the Alzheimer's Association (2020), there are five approved medications, three of which are cholinesterase inhibitors (donepezil, galanthamine, rivastagmine) usually prescribed for early to moderate stages. The other 2 are N-methyl-D-aspartate (NMDA), a receptor antagonist (memantine), and a drug that combines memantine and donepezil, both are prescribed for moderate-to-severe cases. New approaches in AD treatment of are being developed. Among them is one based on β-secretase inhibitors. This type of treatment is thought to be an ideal therapeutic target by blocking the production of β-amyloid protein (a major component of the amyloid plaque), which is believed to play an early and crucial role in all cases of AD (Schelterns and Feldman 2003).